Effect of oral ketoconazole on first-pass effect of nifedipine after oral administration in dogs

Journal of Pharmaceutical Sciences

Volumn 91, Issue 3, 2002, Pages 868-873

  Kuroha, Masanori ^a   Kayaba, Hideki ^a   Kishimoto, Shizuka ^a   Khalil, Waleed F ^a   Shimoda, Minoru ^a   Kokue, Eiichi ^a  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

Author keywords

CYP3A; First pass effect; Ketoconazole; Nifedipine

Indexed keywords

CYTOCHROME P450 3A; EMABERIN L; KETOCONAZOLE; NIFEDIPINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG POTENTIATION; DRUG TISSUE LEVEL; ENZYME ACTIVITY; ENZYME SUBSTRATE; FIRST PASS EFFECT; INTESTINE; MALE; NONHUMAN;

EID: 0036281241     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10086     Document Type: Article

References (23)

1. Oral azole drugs as systemic antifungal therapy
2. Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents
3. Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes
4. Cyclosporin A drug interactions Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes
5. Metabolism of the immunosuppressant tacrolimus in the small intestine: Cytochrome P450, drug interactions, and interindividual variability
6. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole
7. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine
8. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole
9. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism
10. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man
11. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression
12. Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs
13. Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in dogs
14. Sensitive high-performance liquid chromatographic assay for nifedipine in human plasma utilizing ultraviolet detection
15. A pharmacokinetic analysis program (MULTI) for microcomputer
16. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazepines and phenytoin
17. Clinical pharmacokinetics of verapamil, nifedipine, and diltiazem
18. Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver
19. Metabolism of halofantrine to its equipotent metabolite, desbutylhalofantrine, is decreased when orally administered with ketoconazole
20. Effects of ketoconazole on the intestinal metabolism, transport, and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats
21. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells
22. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery
23. Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver